The time of exposure and concentration of the inhibitor were based on the previous use of STAT3-IN-1 in human mammary carcinoma cell lines.23 The assay results showed that the pharmacological inhibition of STAT3 activation also significantly affected the activation of the LIFR reporter (Figure 3c). Here, STAT3 is linked to breast carcinoma.